---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-003071"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2024-01-19T23:59:59+00:00"
generated_at: "2026-06-06T21:10:06.551676+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Dare Bioscience receives Nasdaq delisting notice for bid price below $1.00 per share

## Summary
- Received Nasdaq delisting notice on Jan 17, 2024 for failing to meet minimum $1.00 bid price requirement.
- Company had until Jan 16, 2024 to regain compliance but did not.
- Will request a hearing before Nasdaq Hearing Panel to appeal and stay delisting.
- Hearing typically scheduled 30-45 days after request; no assurance of success.

## SEC filing metadata
- accession: 0001493152-24-003071
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2024-01-19T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000149315224003071/0001493152-24-003071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000149315224003071/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-003071
- JSON: https://secwatch.observer/filing/0001493152-24-003071.json
- Plain text: https://secwatch.observer/filing/0001493152-24-003071.txt

## Key facts
- Listing & Compliance Notices
  Dare Bioscience, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: January 17, 2024, the Staff notified the Company that because the Company did not timely regain compliance with the Minimum Bid Price Requirement, the Company’s common stock is subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearing Panel (the “Panel”). The Company will timely request a hearing before the Panel, which request will stay the delisting of the Company’s common stock pending the decision of the Panel following the hearing and the expiration of any extension period that may be granted by the Panel. Pursuant to published Nasdaq guidance
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401914/000149315224003071/0001493152-24-003071-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.